Bio-Techne Corp

Bio‑Techne insider trading: Herr Amy E.’s small 22‑share net purchase signals confidence amid Q2 2026 earnings, supporting a moderate bullish outlook for the protein‑science & cell‑therapy leader.

Insider buying shows confidence in Bio‑Techne’s 3‑D hydrogel launch, highlighting potential upside despite a high P/E and market volatility.